AF
VKTX icon

Allworth Financial’s Viking Therapeutics VKTX Stock Holding History

Allworth Financial’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.1K Sell
1,360
-920
-40% -$29.7K ﹤0.01% 2424
2026
Q1 		$74.2K Buy
2,280
+1,220
+115% +$39.2K ﹤0.01% 2054
2025
Q4 		$37.3K Buy
1,060
+120
+13% +$4.25K ﹤0.01% 2397
2025
Q3 		$24.7K Sell
940
-15
-2% -$447 ﹤0.01% 2576
2025
Q2 		$25.3K Buy
955
+352
+58% +$9.27K ﹤0.01% 2372
2025
Q1 		$15.5K Buy
603
+126
+26% +$3.98K ﹤0.01% 2216
2024
Q4 		$16.2K Sell
477
-11
-2% -$627 ﹤0.01% 2218
2024
Q3 		$30.9K Buy
488
+6
+1% +$352 ﹤0.01% 1642
2024
Q2 		$24.5K Buy
482
+15
+3% +$983 ﹤0.01% 1752
2024
Q1 		$38.3K Buy
467
+67
+17% +$2.98K ﹤0.01% 1415
2023
Q4 		$7.44K Buy
400
+391
+4,344% +$5.11K ﹤0.01% 2099
2023
Q3 		$100 Buy
+9
New +$129 ﹤0.01% 3344

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Allworth Financial's VKTX Position: Q2 2026 in Review

Allworth Financial reduced its Viking Therapeutics (VKTX) stake by 40% in Q2 2026, selling an estimated $29.7K and leaving 1,360 shares worth $53.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2424.

Allworth Financial first reported a position in VKTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $74.2K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Allworth Financial held 1,360 shares of Viking Therapeutics worth $53.1K as of Q2 2026.
  • Allworth Financial sold 920 Viking Therapeutics shares in Q2 2026, an estimated $29.7K.
  • Viking Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2424 holding.
  • Allworth Financial first reported a position in Viking Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Allworth Financial's Viking Therapeutics position peaked at $74.2K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.